Identification of pyrogallol as a warhead in design of covalent inhibitors for the SARS-CoV-2 3CL protease

The ongoing pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) urgently needs an effective cure. 3CL protease (3CL(pro)) is a highly conserved cysteine proteinase that is indispensable for coronavirus replication, providing an attractive target for developing broad-spectrum antiviral drugs. Here we describe the discovery of myricetin, a flavonoid found in many food sources, as a non-peptidomimetic and covalent inhibitor of the SARS-CoV-2 3CL(pro). Crystal structures of the protease bound with myricetin and its derivatives unexpectedly revealed that the pyrogallol group worked as an electrophile to covalently modify the catalytic cysteine. Kinetic and selectivity characterization together with theoretical calculations comprehensively illustrated the covalent binding mechanism of myricetin with the protease and demonstrated that the pyrogallol can serve as an electrophile warhead. Structure-based optimization of myricetin led to the discovery of derivatives with good antiviral activity and the potential of oral administration. These results provide detailed mechanistic insights into the covalent mode of action by pyrogallol-containing natural products and a template for design of non-peptidomimetic covalent inhibitors against 3CL(pro)s, highlighting the potential of pyrogallol as an alternative warhead in design of targeted covalent ligands. SARS-CoV-2 3CL protease (3CL(pro)) is essential for coronavirus replication and of great interest as an antiviral drug target. Here, the authors show that the naturally occurring flavonoid myricetin is a non-peptidomimetic and covalent inhibitor of 3CL(pro), and they solve crystal structures of 3CL(pro) with myricetin and derivatives, which reveal that the pyrogallol group covalently modifies the catalytic cysteine.

Automated summary

The naturally occurring flavonoid myricetin is identified as a non-peptidomimetic and covalent inhibitor of SARS-CoV-2 3CL protease. Crystal structures reveal the pyrogallol group modifies the catalytic cysteine through covalent binding. This study provides insights into the mechanism of action of pyrogallol-containing natural products and offers a template for designing non-peptidomimetic covalent inhibitors against 3CL proteases.